Non-interventional Study To Evaluate Efficacy And Safety Of Refacto Af In The Standard Prophylaxis Treatment Of Children With Severe Hemophilia A

Trial Profile

Non-interventional Study To Evaluate Efficacy And Safety Of Refacto Af In The Standard Prophylaxis Treatment Of Children With Severe Hemophilia A

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Moroctocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 03 Jul 2017 Planned End Date changed from 15 Sep 2017 to 1 Jan 2018.
    • 03 Jul 2017 Planned primary completion date changed from 15 Sep 2017 to 1 Jan 2018.
    • 03 Jul 2017 Planned initiation date changed from 15 Jun 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top